Latest Pharma and Biotech News
Pharmaceutical
7 July 2025 A Dutch appeals court has ruled that health insurers acted unlawfully in their group tender for three CDK 4/6 inhibitors, reigniting debate over cost-driven drug policies in the Netherlands. The case centered on whether insurers can restrict prescribing choices for innovative cancer drugs that differ in clinical profiles.
Today's issue
Refine Search
Biosimilars
German biosimilars company Formycon has announced that its 2025/2029 corporate bond was significantly oversubscribed due to high demand, leading to an increase in the initially targeted issuance volume from 50 million euros ($59 million) to 70 million euros. 28 June 2025
Pharmaceutical
US biotech Arbutus Biopharma has reacquired the rights to its lead hepatitis B candidate, imdusiran (AB-729), in China, ending a nearly four-year partnership with Qilu Pharmaceutical. 27 June 2025
Biotechnology
Alphabet-founded biotech Calico Life Sciences has struck an exclusive licensing agreement with Chinese drugmaker Mabwell for investigational therapies aimed at interleukin-11 (IL-11), including a Phase I-stage monoclonal antibody targeting age-related conditions. 27 June 2025
Pharmaceutical
German drugmaker Bayer has renewed its partnership with China’s Tsinghua University for another three years, reinforcing its strategy to develop treatments aligned with China’s growing role in global biopharma R&D. 27 June 2025
Biotechnology
US biotech major Biogen today announced new data that reinforce the clinical impact of nusinersen across a broad spectrum of individuals affected by spinal muscular atrophy (SMA). 27 June 2025
Pharmaceutical
Despite calls for the meeting to be delayed, Wednesday’s meeting of the Centers for Disease Control and Prevention's (CDC's) Advisory Committee on Immunization Practices (ACIP) went ahead. 27 June 2025
Biotechnology
In a significant showcase for investors, BeOne Medicines announced major advancements to its industry-leading oncology pipeline during an investor R&D Day. 27 June 2025
Biotechnology
Italian drugmaker Philogen has announced its decision to voluntarily withdraw the application for marketing authorization to the European Medicines Agency (EMA) for Nidlegy(daromun), a biological investigational medicinal product which is intended to be used for the neoadjuvant treatment of adult patients with locally advanced fully resectable melanoma. 27 June 2025
Biosimilars
Indian drugmaker Biocon has announced that Health Canada has granted a Notice of Compliance for Yesafili (aflibercept), a biosimilar to Eylea (aflibercept) injection, in vial and prefilled syringe presentations, 2 mg/0.05 mL. 27 June 2025
Pharmaceutical
Japanese drugmaker Chugai Pharmaceutical today revealed that it has filed a regulatory application with the Ministry of Health, Labor and Welfare (MHLW) for an additional indication of its anti-cancer agent/ALK inhibitor Alecensa (alectinib) for ALK fusion/rearrangement gene-positive unresectable advanced or recurrent solid tumors, including pediatric patients. 27 June 2025
Pharmaceutical
Belgian pharma UCB today announced that the Phase III study investigating the safety and efficacy of adjunctive fenfluramine in CDKL5 deficiency disorder (CDD) met its primary and key secondary endpoints. 27 June 2025
Pharmaceutical
US biopharma company Altimmune saw its share slump almost 55% to $3.48 yesterday, after it announced what it called ‘positive’ top-line results from the IMPACT Phase IIb trial of pemvidutide in metabolic dysfunction-associated steatohepatitis (MASH). 27 June 2025
Biotechnology
US pharma major Merck & Co has secured a key endorsement for its newly approved respiratory syncytial virus (RSV) prevention product, Enflonsia (clesrovimab), as a majority of an influential advisory panel voted to recommend its use in newborns ahead of the 2025-2026 RSV season. 27 June 2025
Pharmaceutical
Rising use of innovative medicines and shifting spending patterns are reshaping the global pharmaceutical landscape, according to a new report from US data analytics group IQVIA. 27 June 2025
Biotechnology
US pharm giant Pfizer today announced positive top-line results from the Phase III BASIS study evaluating Hympavzi (marstacimab) for adults and adolescents living with hemophilia A or B with inhibitors. 26 June 2025
Generics
US insurance giant Cigna has taken fresh legal action against Bristol Myers Squibb, accusing the drugmaker of manipulating the patent system to preserve its monopoly on the multiple myeloma treatment Pomalyst (pomalidomide). 26 June 2025
Biotechnology
Singapore-based biotech Hummingbird Bioscience has out-licensed its lead immunotherapy candidate, HMBD-002, to Australian drug developer Percheron Therapeutics in a deal valued at up to $290 million. 26 June 2025
Biotechnology
The US Food and Drug Administration (FDA) has required and approved updates to the Prescribing Information for Comirnaty (COVID-19 Vaccine, mRNA) manufactured by Pfizer and Spikevax (COVID-19 Vaccine, mRNA) manufactured Moderna to include new safety information about the risks of myocarditis and pericarditis following administration of mRNA COVID-19 vaccines. 26 June 2025
Biotechnology
Cambridge, USA-based ProFound Therapeutics today announced a four-year collaboration with Swiss pharma giant Novartis to discover and develop novel therapeutics for cardiovascular disease leveraging its ProFoundry Platform. 26 June 2025
Biotechnology
Biogen’s salanersen has shown promise in slowing neuronal damage and opening new motor milestones, according to interim findings from a Phase I study. 26 June 2025
All news
Biotechnology
Debra Barker has been named chief medical officer (CMO) at Centauri Therapeutics (Nasdaq: IPSC), a UK immunotherapy company with a proprietary platform technology applicable across a wide range of therapeutic indications. 8 July 2025
Biotechnology
San Francisco, USA-based biotech Centivax, which is developing durable, universal vaccines, today announced the close of a $45 million Series A led by Steve Jurvetson’s Future Ventures, with participation from NFX, BOLD Capital, Base4, Kendall Capital Partners, Amplify Bio, and existing investors. 8 July 2025
Biotechnology
Diagonal Therapeutics, a US biotech focused on correcting dysregulated signaling with clustering antibodies that address the underlying cause of intractable genetic diseases, has announced the appointment of John Lee as chief medical officer (CMO). 8 July 2025
Pharmaceutical
Switzerland-based MetP Pharma, pioneer in nose-to-brain drug delivery for nearly two decades, announced new data highlighting the advantages of its proprietary MetP Technology in delivering neuroactive peptides such as semaglutide directly to the brain via the intranasal route. 8 July 2025
Biosimilars
The US subsidiary of South Korea-based Celltrion today announced that Stoboclo (denosumab-bmwo) and Osenvelt (denosumab-bmwo), biosimilars referencing US biotech major Amgen’s (Nasdaq: AMGN) denosumab brands Prolia and Xgeva, had been launched in the USA. 8 July 2025
Biotechnology
US CAR-T focused biotech CARGO Therapeutics today announced that it has entered into a definitive merger agreement with Concentra Biosciences, initially worth roughly $200 million. The news sent CARGO’s stock up as much as 9.6% to $4.81 in pre-market activity. 8 July 2025
Biotechnology
Having appointed Renée Aguiar-Lucander as its chief executive in April and Maria Törnsén as chief operating officer a month later, Hansa Biopharma has announced the appointment of a chief medical officer (CMO). 8 July 2025
Biotechnology
US biotech Cogent Biosciences closed Monday’s trading 23% higher, following the company’s announcement of positive top-line results from the registration-directed part two of the SUMMIT clinical trial of bezuclastinib in patients with non-advanced systemic mastocytosis (NonAdvSM). 8 July 2025
Pharmaceutical
Swiss pharma giant Novartis today announced Coartem (artemether-lumefantrine) Baby has been approved by Swissmedic as the first malaria medicine for newborns and young infants. 8 July 2025
Pharmaceutical
Shares in Japanese drugmaker Otsuka Holdings closed nearly 2% lower Tuesday, after disappointing clinical trial results from one of its subsidiaries. 8 July 2025
Biotechnology
French biotech Nanobiotix’ (shares were up nearly 7% at 4.44 euros in early trading, after the company announced two important developments that aim to reinforce the global positioning of potential first-in-class radioenhancer JNJ-1900 (NBTXR3), which is licensed by Janssen Pharmaceutica, a Johnson & Johnson subsidiary. 8 July 2025
Biotechnology
Shares of US clinical-stage biotech Apogee Therapeutic closed down 17.3% at $39.24 yesterday, despite announcing positive 16-week data from Part A of the Phase II APEX clinical trial of APG777, a potential best-in-class anti-interleukin (IL)-13 antibody, in patients with moderate-to-severe atopic dermatitis (AD). 8 July 2025
Pharmaceutical
Eli Lilly led the way in pharma M&A during June. 7 July 2025
Biotechnology
Japanese drugmaker Chugai Pharmaceutical has entered into a joint research and license agreement to develop novel therapies for age-related diseases with Singapore-based biotech Gero. 7 July 2025
Biotechnology
The GPRC5D-directed therapies market is witnessing robust growth, driven by high unmet need in relapsed/refractory multiple myeloma, according to a report on the field by DelveInsight. 7 July 2025
Biotechnology
Actinogen Medical (ASX: ACW), an Australian biotech, announced that the 100th participant in its pivotal XanaMIA Phase IIb/III randomized trial of Xanamem (emestedastat) for Alzheimer's disease (AD) has now passed all screening tests and is scheduled for randomization and treatment in July. 7 July 2025
Pharmaceutical
USA and UK-based KalVista Pharmaceuticals today announced that the US Food and Drug Administration (FDA) has approved Ekterly (sebetralstat), a novel plasma kallikrein inhibitor, for the treatment of acute attacks of hereditary angioedema (HAE) in adult and pediatric patients aged 12 years and older. 7 July 2025
Pharmaceutical
A nasal COVID-19 vaccine developed by US biotech CyanVac has produced encouraging results in an early trial, showing potential to offer broader immunity and easier delivery than current injections. 7 July 2025
Pharmaceutical
The pulmonary arterial hypertension (PAH) market across the seven major markets (7MM: USA, France, Germany, Italy, Spain, UK and Japan) is poised to grow at a compound annual growth rate (CAGR) of 2.0% from $7.6 billion in 2024 to $9.3 billion in 2034. 7 July 2025
Pharmaceutical
Swissmedic has introduced a fast-track review process for clinical trial applications, aiming to speed up access to innovative treatments in Switzerland. 7 July 2025
Sign up to receive email updates
Join industry leaders for a daily roundup of biotech & pharma news
Copyright © The Pharma Letter 2025 | Headless Content Management with Blaze